Cannabis Stocks Watchlist: Keep an Eye on Aurora Cannabis

See how cannabis stocks such as Aurora Cannabis, Cronos Group and Tilray performed in the market this week.
Author:
Updated:
Original:

The House passed legislation intending to decriminalize marijuana and expunge nonviolent marijuana-related records. Despite this monumental legislation, it would be dead on arrival in the Senate if Republicans maintain a majority.

Marijuana stocks were mixed after the bill was passed in the House. 15 states in the U.S. have legalized cannabis for recreational use.

For more in-depth coverage of the cannabis sector including buy and sell recommendations and investment strategies, follow Debra Borchardt on Real Money.

Here is a list of the cannabis stocks to watch and their performance from this past week by the percentage change at the close of trading on Dec. 4.

Aurora Cannabis Inc | Increased +4.01% | Price $10.89

Aurora Cannabis  (ACB) - Get Report shares were rising after the U.N. voted to remove cannabis from its Schedule IV designation, leading to a rally in cannabis stocks.

TheStreet Quant Ratings rates Aurora Cannabis Inc. as a Sell with a rating score of D-.

Arena Pharmaceuticals | Increased +1.75% | Price $67.05

Arena Pharmaceuticals  (ARNA) - Get Report announced that its president would speak at the Evercore ISI HealthCONx Conference this week.

TheStreet Quant Ratings rates Arena Pharmaceuticals as a Hold with a rating score of C.

Cronos Group Inc | Increased +1.89% | Price $8.63

Cronos Group  (CRON) - Get Report is up 43% since Election Day and the popular cannabis stock pick.

TheStreet Quant Ratings rates Cronos Group as a Sell with a rating score of D.

Tilray Inc | Increased +1.18% | Price $8.60

Shares of Tilray  (TLRY) - Get Report climbed Wednesday after the cannabis company said it entered into a co-promotion agreement with Hormosan.

TheStreet Quant Ratings rates Tilray as a Sell with a rating score of D.

Cara Therapeutics | Increased +0.87% | Price $15.08

Cara Therapeutics  (CARA) - Get Report reported a loss but beat earnings estimates.

TheStreet Quant Ratings rates Cara Therapeutics as a Sell with a rating score of D.

Canopy Growth Corp | Decreased -1.41% | Price $27.38

Canopy Growth  (CGC) - Get Report was rising after the U.N. voted to remove cannabis from its Schedule IV designation, leading to a rally in cannabis stocks.

TheStreet Quant Ratings rates Canopy Growth Corp as a Hold with a rating score of C.

GW Pharma | Increased +6.00% | Price $137.49

GW Pharma  (GWPH) - Get Report reported quarterly financial results in early Nov. and shares have been rising ever since.

TheStreet Quant Ratings rates GW Pharma as a Sell with a rating score of D+.